Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-15
Target enrollment:
Participant gender:
Summary
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (\<16yo max 15mg, \>16yo max 30mg) x 1 dose.
Phase:
PHASE4
Details
Lead Sponsor:
Children's Blood and Cancer Center at Dell Children's Medical Center